Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1
At five-year follow-up, first-line cemiplimab monotherapy continued to show durable clinical benefits versus chemotherapy in patients with advanced NSCLC with 50% or higher PD-L1. Patients with 90% or higher PD-L1 derived the largest clinical benefits.
Authors
- Mahmut Gumus (ORCID: https://orcid.org/0000-0002-4323-0215)
- Ahmet Sezer (ORCID: https://orcid.org/0000-0002-6445-1439)
- Gwo Fuang Ho (ORCID: https://orcid.org/0000-0002-2620-9174)
- Igor Bondarenko (ORCID: https://orcid.org/0000-0002-7071-2471)
- Frank Seebach
- Mustafa Özgüroğlu (ORCID: https://orcid.org/0000-0002-8417-8628)
- Michael Schenker (ORCID: https://orcid.org/0000-0003-2645-6391)
- Miranda Gogishvili (ORCID: https://orcid.org/0000-0002-5143-6379)
- Israel Lowy (ORCID: https://orcid.org/0000-0002-5421-2485)
- Saadettin Kılıçkap (ORCID: https://orcid.org/0000-0003-1637-7390)
- Heather Magnan (ORCID: https://orcid.org/0000-0003-2422-9769)
- Jean‐François Pouliot (ORCID: https://orcid.org/0000-0002-9125-0456)
- İrfan Çiçin (ORCID: https://orcid.org/0000-0002-7584-3868)
- Manika Kaul
- Ki Dong Kim (ORCID: https://orcid.org/0000-0002-7642-1149)
- Javier J. Pérez (ORCID: https://orcid.org/0000-0002-7628-6610)
- Ana Baramidze (ORCID: https://orcid.org/0000-0003-3606-3268)
- Yaroslav Kulyaba
- Kasimova Zyuhal
- Marina Chiara Garassino (ORCID: https://orcid.org/0000-0002-3821-5598)
- Yuntong Li (ORCID: https://orcid.org/0009-0004-1036-1966)
- Marina Nechaeva
- Roxana-Ioana Scheusan
- Cong Zhu (ORCID: https://orcid.org/0009-0000-6077-4647)
Institutions
- Regeneron (United States) (US)
- Başkent University (TR)
- University of Malaya (MY)
- University of Chicago (US)
- National Institute of Emergency Medicine "Pirogov" (BG)
- Istanbul University-Cerrahpaşa (TR)
- Istinye University (TR)
- International Institute of Management Arkhangelsk (RU)
- Istanbul Medeniyet University (TR)
- Dnipro State Medical University (UA)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1016/j.jtho.2025.03.033
- Citations
- 14
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 14.64
Funders
- Sanofi
- Regeneron Pharmaceuticals